Alyeska Investment Group
SONN

Alyeska Investment Group’s Sonnet BioTherapeutics SONN Stock Holding History

Alyeska Investment Group’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,408
Closed -$343K – 623
2023
Q1 		$343K Buy
+5,408
New +$875K ﹤0.01% 422

Other funds holding SONN

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Alyeska Investment Group's SONN Position: Q2 2023 in Review

Alyeska Investment Group sold out of Sonnet BioTherapeutics (SONN) in Q2 2023, closing a stake of 5,408 shares — an estimated $343K sold.

Alyeska Investment Group first reported a position in SONN in Q1 2023 and held it in 1 quarter. The position peaked at $343K in Q1 2023. 21 funds tracked by Wall St. Rank hold SONN as of Q2 2023.

  • Alyeska Investment Group reported no remaining Sonnet BioTherapeutics position as of Q2 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 5,408 Sonnet BioTherapeutics shares in Q2 2023, an estimated $343K.
  • Alyeska Investment Group first reported a position in Sonnet BioTherapeutics in Q1 2023 and held it in 1 quarter.
  • Alyeska Investment Group's Sonnet BioTherapeutics position peaked at $343K in Q1 2023.
  • 21 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2023.

Based on Alyeska Investment Group's 13F filing for Q2 2023, filed 14 Aug 2023.